Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

On 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of ...